Clinical Trial

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) will synergize with local therapy as well as treat micro metastatic disease and improve one year progression-free survival rates for participants and optimize local control.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-05-04; most recent amendment 2026-01-15.
Status change: Not Yet Recruiting → Recruiting 2022-09-27
Trial Details
NCT Number NCT05366829
Lead Sponsor Rutgers, The State University of New Jersey
Collaborators: BioGene Pharmaceutical Ltd., Natera, Inc.
Conditions Carcinoma, Hepatocellular, Liver Cell Carcinoma
Enrollment 35 participants
Start Date 2022-07-25
Primary Completion 2027-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-20